About Sloning Established in 2001 and based in Puchheim, close-by Munich, Germany, Sloning BioTechnology is a protein engineering
company and leading supplier of highly innovative synthetic biology tools.
Biocatalysts company Codexis (NasdaqGS:CDXS) disclosed on Monday the execution of a platform technology license agreement for its proprietary CodeEvolver protein engineering
platform technology with GlaxoSmithKline (GSK).
The addition of Bio-IT World Europe and PEGS Europe: The Protein Engineering
Summit, both being held in Europe for the first time, brings exciting new session content to BIOTECHNICA", says Stephan Kuhne, member of the Board at Deutsche Messe AG, Hannover.
Life science measurement company Agilent Technologies (NYSE:A) reported on Wednesday the launch of The QuikChange HT Protein Engineering
System under a series of novel synthetic biology solutions for rational mutagenesis.
His current scientific interests mainly focus on protein engineering
and design, aimed at isolating biological macromolecules with prescribed functions via rational design or high throughput screening of combinatorial peptide, microbody and enzyme libraries.
This advanced protein engineering
technology is expected to enable Novozymes to bring down discovery time and expand its project portfolio.
He has a wealth of experience in protein engineering
, including monoclonal antibody production and conjugation, gained at Affibody, Genentech and Pharmacia.
Within the frame of the collaboration, AliX will provide SOSHO with its protein engineering
expertise and SOSHO will apply its breakthrough crystallization technology.
The company is utilising its extensive protein engineering
expertise--the process of changing the sequence of a gene coding for a protein in order to bring about desirable changes in function--to make these multi-specific therapeutics function in a way that most benefit patients.
services provider Isogenica Ltd reported on Monday that the company has signed a new agreement for the development of antimicrobial peptide drugs for the potential treatment of resistant bacteria such as MRSA and C Difficile.
PhaseBio), located in Research Triangle Park, NC, is a development stage, privately held protein engineering
company focused on developing the next generation of biopharmaceuticals.
TF2 is a new generation of bispecific antibodies constructed using Immunomedics' patented Dock-and-Lock (DNL) protein engineering